What is VINC's current stock price?

VINC (Vincerx Pharma, Inc.) is currently trading at $0.01 with a market cap of $67.3K.

What sector is Vincerx Pharma, Inc. in?

Vincerx Pharma, Inc. (VINC) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VINC a good stock to buy?

Analysts have a Buy consensus on VINC with a price target of $3.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VINC Vincerx Pharma, Inc.

Healthcare

$0.01+1.18%ClosedMarket Cap: $67,260

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.03

P/S

0.06

EV/EBITDA

0.37

DCF Value

$0.78

FCF Yield

-15811.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

50.0%

Operating Margin

-1138.6%

Net Margin

-1216.7%

ROE

-542.5%

ROA

-277.3%

ROIC

-588.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.0M	$—
Q4 null	$1.1M	$-8.0M	$—
FY null	$0.00	$-30.1M	$—
Q3 null	$0.00	$-7.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$2.00 - $4.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Haas Kevinofficer: Acting Chief Financial Officer

SellMon Jan 06

Haas Kevinofficer: Acting Chief Financial Officer

SellMon Jan 06

THOMAS TOM Cofficer: See Remarks

SellWed Aug 14

THOMAS TOM Cofficer: See Remarks

SellWed Aug 14

THOMAS TOM Cofficer: See Remarks

SellWed Aug 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.46

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Peers